GTBP — GT Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $5.93m
- -$3.88m
Annual cashflow statement for GT Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -38.6 | -28.3 | -58 | -20.9 | -7.6 |
| Depreciation | |||||
| Non-Cash Items | 32 | 21.6 | 35.2 | 7.66 | -3.08 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.94 | -0.596 | 7.25 | -1.99 | 1.82 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.66 | -7.26 | -15.6 | -15.2 | -8.85 |
| Capital Expenditures | 0 | — | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.2 | 0 | -23 | 12.1 | -2.01 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.2 | 0 | -23 | 12.1 | -2.01 |
| Financing Cash Flow Items | 0 | — | — | -0.224 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.43 | 12.5 | 42.3 | -0.224 | 6.27 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.032 | 5.27 | 3.67 | -3.3 | -4.59 |